Geron Corp
geron.comGeron Corp (NASDAQ: GERN) is a commercial-stage biopharmaceutical company that develops and sells a telomerase inhibitor therapy for blood cancers. Revenue comes from product sales of RYTELO (imetelstat), which received FDA approval on June 6, 2024, for adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents. Product revenue, net, grew from $76.5M in FY2024 to $183.6M in FY2025, representing 99.9% of total FY2025 revenues of $183.9M. A small royalty stream contributed $258K in FY2025. The company reported a net loss of $83.5M in FY2025, with selling, general and administrative expenses of $159.3M and research and development expenses of $71.4M. Geron is commercializing RYTELO in the U.S. and planning commercialization in the EU, with the addressable market limited to lower-risk MDS patients meeting the approved indication criteria.
Products & Services
RYTELO (imetelstat), an FDA-approved telomerase inhibitor for lower-risk MDS with transfusion-dependent anemia. Approved June 6, 2024. EU commercialization planned as of the 10-K filed 2026-03-02.
Revenue Model
Transactional product revenue from sales of RYTELO to patients with lower-risk MDS in the U.S., plus a small royalty stream. Product revenue, net was $183.6M in FY2025 versus $76.5M in FY2024. Royalties were $258K in FY2025.
Customers & Markets
Adult patients with lower-risk MDS requiring four or more red blood cell units over eight weeks who have not responded to or are ineligible for erythropoiesis-stimulating agents. End market is hematology/oncology in the U.S., with EU expansion planned.
Geographic Exposure
Primarily U.S. commercial operations as of FY2025. EU commercialization planned but not yet generating revenue as of the 10-K filed 2026-03-02.
Financial Snapshot
Loading...
